UK's BBI joins Inverness growing family
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations has completed the acquisition of Cardiff, Wales-based diagnostics company BBI. Inverness paid at total of £63.2m ($123.2m) in cash and around 251,300 shares of its common stock for the UK developer of noninvasive lateral flow tests and gold reagents. In December 2007, BBI became one in a string of acquisitions made by Inverness throughout the year (see Clinica No 1286, p 3).